Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor. The company has successfully completed two Phase 3 trials with deuruxolitinib in adults with Alopecia Areata, a serious autoimmune dermatological disease. It is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. Concert Pharmaceuticals was founded in 2006 and is based in Lexington, Massachusetts.
PREVIOUS DEAL
| DATE |
TARGET |
DEAL TYPE |
VALUE |
| 2017-03-06 |
Concert Pharmaceuticals - CTP-656
Lexington, Massachusetts, United States
Concert Pharmaceuticals, Inc. - CTP-656 was developed by Concert through the application of deuterium chemistry to modify Vertex’s CFTR potentiator, ivacaftor. Ivacaftor was discovered by Vertex scientists and is approved in the U.S., Europe, Canada and Australia for people with CF who have specific mutations in the CFTR gene. CTP-656 has the potential to play a key role in future once-daily combination regimens to treat CF. Concert is currently conducting a Phase 2 study of CTP-656 in people with CF who have gating mutations. As part of the agreement, Vertex will acquire rights to all of Concert’s other CF research and preclinical programs.
|
Sell |
$160M |
